Sandbox MEN 2 epi

__NOTOC_

Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Sandbox MEN 2 epi On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox MEN 2 epi All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox MEN 2 epi
CDC on Sandbox MEN 2 epi
Sandbox MEN 2 epi in the news
Blogs on Sandbox MEN 2 epi
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Sandbox MEN 2 epi

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Prevalence

• • Worldwide, the prevalence of (insert disease state here) is _____ per 100,000 persons.
  • In developed countries, the prevalence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
  • In developed countries, the prevalence of (insert disease state here) is _____ per 100,000 persons.
  • In developing countries/ Africa, the prevalence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average prevalence of _____ per 100,000 persons.
  • In developing countries/ Africa, the prevalence of (insert disease state here) is _____ per 100,000 persons.

Incidence

• • Worldwide, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
  • Worldwide, the incidence of (insert disease state here) is _____ per 100,000 persons.
  • In developed countries, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
  • In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.
  • In developing countries/ Africa, the incidence of (insert disease state here) ranges from a low of _____ per 100,000 persons to a high of _____ per 100,000 persons with an average incidence of _____ per 100,000 persons.
  • In developing countries/ Africa, the incidence of (insert disease state here) is _____ per 100,000 persons.

Age

• The prevalence of (insert disease state here) increases/decreases with age.

Gender

• The prevalence and incidence of (insert disease state here) does not vary by gender.
• Men and women are affected equally by (insert disease name here).
• (Insert disease state here) is more prevalent in men women.
• The prevalence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.
• The incidence of (insert disease state here) among men is ____ per 100,000, while it is _____ per 100,000 among women.

Race

• The prevalence of (insert disease state here) does not vary by race.
• (Insert disease state here) is more prevalent in the ____race and ____ races.

Developed Countries

• Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.

Developing Countries

• Incidence, prevalence, and geographical distribution or areas of interest can be mentioned, as well as the impact the disease has on society.